Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0V4TK
|
||||
Former ID |
DNC014065
|
||||
Drug Name |
N-(6-methylpyridin-2-yl)-6-phenylnicotinamide
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C18H15N3O
|
||||
Canonical SMILES |
CC1=NC(=CC=C1)NC(=O)C2=CN=C(C=C2)C3=CC=CC=C3
|
||||
InChI |
1S/C18H15N3O/c1-13-6-5-9-17(20-13)21-18(22)15-10-11-16(19-12-15)14-7-3-2-4-8-14/h2-12H,1H3,(H,20,21,22)
|
||||
InChIKey |
SJCQCBNYZNABCO-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Metabotropic glutamate receptor 5 | Target Info | Inhibitor | [1] | |
KEGG Pathway | Calcium signaling pathway | ||||
Neuroactive ligand-receptor interaction | |||||
Gap junction | |||||
Long-term potentiation | |||||
Retrograde endocannabinoid signaling | |||||
Glutamatergic synapse | |||||
Huntington's disease | |||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
Metabotropic glutamate receptor group III pathway | |||||
Metabotropic glutamate receptor group I pathway | |||||
Endogenous cannabinoid signaling | |||||
Reactome | G alpha (q) signalling events | ||||
Class C/3 (Metabotropic glutamate/pheromone receptors) | |||||
WikiPathways | Hypothetical Network for Drug Addiction | ||||
GPCRs, Class C Metabotropic glutamate, pheromone | |||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | J Med Chem. 2009 Jun 11;52(11):3563-75.Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.